No abstract available.
Drug Therapy* ; Lymphoma*

No abstract available.
Drug Therapy ; Lymphoma*

Follicular lymphoma is a common pathological subtypes of lymphoma, it ranked only second to diffuse large B-cell lymphoma, accounts for 22% of non Hodgkin's lymphoma. Follicular lymphoma is a displaying biologically and clinically diverse disease. Patients may present indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden. Decision-making to treat in the frontline is based on histology manifestation, tumor burden and patient symptoms. Treatment for follicular lymphoma includes radiotherapy, chemotherapy, immunological therapy and autologous stem cell transplantation or allogeneic stem cell transplantation.Radiation therapy is the first treatment of early stage follicular lymphoma. For advanced follicular lymphoma chemotherapy, chemotherapy combined immunotherapy or immune radiotherapy, stem cell transplantation may be chosen. In recent years, drugs for lymphoma including bortezomib, lenalidomide, Ofatumumab, Epratuzumab and so on, and the therapeutic scheme present more and more update. In this article the advances of treatment for follicular lymphoma are summarzied.
Humans ; Lymphoma, Follicular ; therapy

Humans ; Lymphoma ; therapy

No abstract available.
Drug Therapy* ; Lymphoma*

NK/T cell lymphoma, a rare type of non-Hodgkin's lymphoma, is a highly aggressive disease with poor prognosis. Clinically, it is classified into nasal, non-nasal, and aggressive lymphoma/leukemia subtypes. They are characterized by geographic distribution and are universally associated with Epstein-Barr virus (EBV) infection. Due to its low occurrence and dismal clinical outcome, no therapeutic strategy is currently identified in this disease. Combined chemotherapy and radiotherapy have better effects for stage I/II nasal NK cell lymphoma. As for stage III/IV nasal NK cell lymphoma and non-nasal, and aggressive subtypes, chemotherapy is the main treatment method. Recently, some studies have demonstrated promising outcomes in the selected cases by high-dose chemotherapy supplemented with auto- or allo-HSCT.
Humans ; Lymphoma, Non-Hodgkin ; classification ; therapy ; Lymphoma, T-Cell ; therapy

No abstract available.
Drug Therapy ; Lymphoma* ; Wernicke Encephalopathy*

Humans ; Lymphoma ; diagnosis ; therapy ; Molecular Targeted Therapy

Although involvement of the testis by generalized lymphoma is usual, especially in the terminal stage or the disease. testicular involvement as a initial manifestation of malignant lymphoma is uncommon. approximately 5% of testicular tumor. We report a case of malignant lymphoma with first manifestation in the testis, clinical stage II b, which was treated with radical orchiectomy, systemic chemotherapy and radiation therapy. This case was followed up by C-T.
Drug Therapy ; Lymphoma ; Lymphoma, Non-Hodgkin* ; Orchiectomy ; Testis*

Lymphoma is one of the most common malignancies in China. In China, there were 6 829 new Hodgkin lymphoma cases and 2 807 deaths in 2020, with 92 834 new non-Hodgkin lymphoma cases and 54 351 deaths. Due to the complicated pathological subtypes and heterogeity, the treatment strategies for lymphoma vary largely. In recent years, with the deep understanding for the nature of lymphoma, much research progress has been achieved in the diagnosis and treatment, leading to a remarkable improvement in survival outcome of patients. In order to update the progress in the treatment of lymphoma worldwide timely, and further improve the level of standardized diagnosis and treatment of lymphoma in China, the China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical practice guideline for lympoma in China (2021 Edition)" .
China/epidemiology* ; Hodgkin Disease/drug therapy* ; Humans ; Lymphoma/therapy* ; Lymphoma, Non-Hodgkin/drug therapy* ; Medical Oncology